BGNE – beigene, ltd. - american depositary shares (US:NASDAQ)

News

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
BeiGene, Ltd. (NASDAQ: BGNE) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $254.00 to $260.00. They now have a "buy" rating on the stock.
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight [Yahoo! Finance]
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com